PharmTech Drug Digest 11.20
News|Articles|November 19, 2026

Our 2026 Workforce Survey Is Open

Listen
0:00 / 0:00

Key Takeaways

  • Biopharma functions spanning CMC through supply chain are being surveyed to quantify workforce sentiment during an unstable operating environment.
  • Core domains include compensation, job satisfaction, retention risk, and perceived security amid layoffs, mergers, and manufacturing-site rationalization.
SHOW MORE

How confident is the bio/pharma workforce heading into 2027? PharmTech wants to find out, and we need your input.

The 2026 Workforce Survey is now open to professionals across CMC, manufacturing, quality, regulatory, R&D, and supply chain. Its 33 questions cover the issues shaping your career right now: compensation and job satisfaction, job security amid layoffs, mergers, and site closures, and whether you’re thinking about making a move. We also want to know how AI is changing your daily work, whether your employer is providing the tools and training you need, and how tariffs, most-favored-nation pricing, and onshoring are affecting your company. Plus, we’re asking for your read on FDA predictability and your outlook for the industry and hiring in 2027.

Your answers will help paint a clear picture of how peers at startups, large pharma companies, and CDMOs are experiencing a turbulent year, and what they expect next.

Take the survey today and add your voice!


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.